Selected article for: "antiviral therapy and membrane oxygenation"

Author: Shimizu, Masaru; Hashimoto, Satoru
Title: Peripheral oxygen saturation to inspiratory oxygen fraction ratio-based identification of critically ill coronavirus disease patients for early therapeutic interventions
  • Cord-id: zfonh37o
  • Document date: 2021_8_15
  • ID: zfonh37o
    Snippet: BACKGROUND: Early identification of critically ill coronavirus disease (COVID-19) patients in clinical settings is crucial in reducing the mortality rate. Therefore, this study aimed to determine whether the saturation of peripheral oxygen (SpO(2)) to fraction of inspiratory oxygen (FiO(2)) ratio (SF ratio) at admission is useful for the early identification of severe COVID-19. METHODS: This single-center, retrospective, observational study conducted at the University Hospital, Kyoto, Japan, inc
    Document: BACKGROUND: Early identification of critically ill coronavirus disease (COVID-19) patients in clinical settings is crucial in reducing the mortality rate. Therefore, this study aimed to determine whether the saturation of peripheral oxygen (SpO(2)) to fraction of inspiratory oxygen (FiO(2)) ratio (SF ratio) at admission is useful for the early identification of severe COVID-19. METHODS: This single-center, retrospective, observational study conducted at the University Hospital, Kyoto, Japan, included 26 patients diagnosed with COVID-19 between January 24 and May 6, 2020. COVID-19 severity was classified into two groups based on the SF ratio: ≤ 235 (moderate to severe disease: low group) and > 235 (normal to mild disease: high group). The characteristics, laboratory data, and outcomes of the patients were examined retrospectively and compared between the groups. RESULTS: Of the 26 patients [median age 51.5 years, interquartile range 35.8–67.0], 6 were in the low group (23%) and 20 in the high group (77%). The low group had a higher respiratory rate than the high group (p < 0.05). Blood tests immediately after admission showed that the low group had significantly lower albumin (p < 0.01), and higher lactate dehydrogenase (p < 0.01), C-reactive protein (p < 0.01), and D-dimer (p < 0.01) levels than the high group. Moreover, all patients received antiviral agents; four received continuous renal replacement therapy and invasive positive pressure ventilation, one received extracorporeal membrane oxygenation, and two died in the low group. CONCLUSION: SF ratio measurement at admission could assist clinicians in the early identification of severe COVID-19, which in turn can lead to early therapeutic interventions.

    Search related documents:
    Co phrase search for related documents
    • abnormal value and admission test: 1
    • abnormal value and admission value: 1, 2
    • abnormal value and liver damage: 1, 2
    • acid amplification test and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acid amplification test and admission treatment: 1
    • acute kidney injury and admission respiratory rate: 1, 2, 3, 4
    • acute kidney injury and admission severe condition: 1
    • acute kidney injury and admission symptom: 1, 2, 3, 4
    • acute kidney injury and admission test: 1, 2, 3
    • acute kidney injury and admission treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute kidney injury and admission value: 1, 2, 3, 4, 5, 6
    • acute kidney injury and liver damage: 1, 2, 3, 4, 5, 6
    • acute kidney injury risk and admission respiratory rate: 1
    • acute respiratory syndrome and admission common symptom: 1, 2
    • acute respiratory syndrome and admission respiratory rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute respiratory syndrome and admission sf ratio: 1
    • acute respiratory syndrome and admission symptom: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and admission test: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and liver damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25